Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC

NCT03341845 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Renal Cell Carcinoma

Interventions

DRUG: Axitinib
DRUG: Avelumab

Sponsor

The Netherlands Cancer Institute

Collaborators

[object Object]